The report highlights Demant's strong performance in the U.S. Department of Veterans Affairs (VA) channel, driven by the successful May launch of the Oticon Zeal hearing aid. Oticon captured a 22.6% value market share, its highest level in over five years.
Key Takeaways
- 1.Oticon (Demant) achieved a 22.6% value market share in the VA channel in May 2026, the highest in over five years.
- 2.Demant's VA revenue for May increased 36% Y/Y, driven by the launch of Oticon Zeal and separately priced chargers.
- 3.Pricing for Oticon Zeal is $695, representing a significant premium to competitor ITE products.
Table of Contents
- EUROPE HEALTHCARE: MEDICAL TECHNOLOGY
- Summary charts
- Valuation & risks
- Disclosure Appendix
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Richard Felton, CFALauren Mitchell
Securities
DEMANT.COSOON.S
Themes
VA Channel Performance
Regions
EuropeUnited States